ALK R1275Q (Q28370067)

From Wikidata

Jump to navigation Jump to search

genetic variant

ARG1275GLN
R1275Q
RS113994087

Language	Label	Description	Also known as
English	ALK R1275Q	genetic variant	ARG1275GLN R1275Q RS113994087

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

human chromosome 2

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

29432664

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

29432664

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

positive therapeutic predictor for

medical condition treated

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1270

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

medical condition treated

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/39

Activating mutations in ALK provide a therapeutic target in neuroblastoma

medical condition treated

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/143

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

medical condition treated

determination method or standard

CIViC evidence level D

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1331

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

negative therapeutic predictor for

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/48

Activating mutations in ALK provide a therapeutic target in neuroblastoma

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_004304.4:c.3824G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

NP_004295.2:p.Arg1275Gln

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

NC_000002.11:g.29432664C>T

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

ENST00000389048.3:c.3824G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/9

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28370067&oldid=2014797891"